| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Advances in targeting the WNT/β-catenin signaling pathway in cancer
|
Chatterjee, Avradip
|
|
|
27 |
1 |
p. 82-101
|
artikel
|
| 2 |
Agonist antibody discovery: Experimental, computational, and rational engineering approaches
|
Schardt, John S.
|
|
|
27 |
1 |
p. 31-48
|
artikel
|
| 3 |
AI for drug discovery is advancing rapidly: We need smart biology for it to fulfill its mission
|
Ushio, Misti
|
|
|
27 |
1 |
p. 1-2
|
artikel
|
| 4 |
Artificial intelligence-enhanced drug design and development: Toward a computational precision medicine
|
Moingeon, Philippe
|
|
|
27 |
1 |
p. 215-222
|
artikel
|
| 5 |
A systematic comparison of hepatobiliary adverse drug reactions in FDA and EMA drug labeling reveals discrepancies
|
Wu, Yue
|
|
|
27 |
1 |
p. 337-346
|
artikel
|
| 6 |
Building better biobetters: From fundamentals to industrial application
|
Torres-Obreque, Karin M.
|
|
|
27 |
1 |
p. 65-81
|
artikel
|
| 7 |
Building HTA insights into the drug development plan: Current approaches to seeking early scientific advice from HTA agencies
|
Wang, Ting
|
|
|
27 |
1 |
p. 347-353
|
artikel
|
| 8 |
Can preclinical drug development help to predict adverse events in clinical trials?
|
Chi, Lap Hing
|
|
|
27 |
1 |
p. 257-268
|
artikel
|
| 9 |
Combining repurposed drugs to treat colorectal cancer
|
Duarte, Diana
|
|
|
27 |
1 |
p. 165-184
|
artikel
|
| 10 |
Contents page 1
|
|
|
|
27 |
1 |
p. i
|
artikel
|
| 11 |
Contents page 2
|
|
|
|
27 |
1 |
p. ii-iii
|
artikel
|
| 12 |
Developing inhaled drugs for respiratory diseases: A medicinal chemistry perspective
|
Pasqua, Elisa
|
|
|
27 |
1 |
p. 134-150
|
artikel
|
| 13 |
Dual-target inhibitors of bromodomain-containing protein 4 (BRD4) in cancer therapy: Current situation and future directions
|
Jin, Wenke
|
|
|
27 |
1 |
p. 246-256
|
artikel
|
| 14 |
Durable cell and gene therapy potential patient and financial impact: US projections of product approvals, patients treated, and product revenues
|
Young, Colin M.
|
|
|
27 |
1 |
p. 17-30
|
artikel
|
| 15 |
Evaluating the performance of drug-repurposing technologies
|
Schuler, James
|
|
|
27 |
1 |
p. 49-64
|
artikel
|
| 16 |
Factors influencing the choice of monoclonal antibodies for antibody–drug conjugates
|
Hasan, Md. Mahbub
|
|
|
27 |
1 |
p. 354-361
|
artikel
|
| 17 |
FVIII at the crossroad of coagulation, bone and immune biology: Emerging evidence of biological activities beyond hemostasis
|
Cadé, Marie
|
|
|
27 |
1 |
p. 102-116
|
artikel
|
| 18 |
Histamine 2 receptors in cardiovascular biology: A friend for the heart
|
Saheera, Sherin
|
|
|
27 |
1 |
p. 234-245
|
artikel
|
| 19 |
Key considerations in formulation development for gene therapy products
|
Mohammad, Rafi
|
|
|
27 |
1 |
p. 292-303
|
artikel
|
| 20 |
Machine-learning methods for ligand–protein molecular docking
|
Crampon, Kevin
|
|
|
27 |
1 |
p. 151-164
|
artikel
|
| 21 |
Manifold medicine: A schema that expands treatment dimensionality
|
Ung, Choong Yong
|
|
|
27 |
1 |
p. 8-16
|
artikel
|
| 22 |
Opportunities for overcoming tuberculosis: Emerging targets and their inhibitors
|
Yang, Liu
|
|
|
27 |
1 |
p. 326-336
|
artikel
|
| 23 |
Organoids in modelling infectious diseases
|
Shpichka, Anastasia
|
|
|
27 |
1 |
p. 223-233
|
artikel
|
| 24 |
Positron emission tomographic imaging in drug discovery
|
Ghosh, Krishna Kanta
|
|
|
27 |
1 |
p. 280-291
|
artikel
|
| 25 |
Recent advancements in mass spectrometry for higher order structure characterization of protein therapeutics
|
Chen, Guodong
|
|
|
27 |
1 |
p. 196-206
|
artikel
|
| 26 |
Receptors and ligands for herpes simplex viruses: Novel insights for drug targeting
|
Huang, Yiwei
|
|
|
27 |
1 |
p. 185-195
|
artikel
|
| 27 |
Renal cell carcinoma therapy: Current and new drug candidates
|
Pontes, Olívia
|
|
|
27 |
1 |
p. 304-314
|
artikel
|
| 28 |
Self-reporting data assets and their representation in the pharmaceutical industry
|
Della Corte, Dennis
|
|
|
27 |
1 |
p. 207-214
|
artikel
|
| 29 |
Sequestsome-1/p62-targeted small molecules for pancreatic cancer therapy
|
Cuyler, Jacob
|
|
|
27 |
1 |
p. 362-370
|
artikel
|
| 30 |
The past, present, and future of enzyme-based therapies
|
Hennigan, Jennifer N.
|
|
|
27 |
1 |
p. 117-133
|
artikel
|
| 31 |
TNF-α: The shape of small molecules to come?
|
Dömling, Alexander
|
|
|
27 |
1 |
p. 3-7
|
artikel
|
| 32 |
Towards Pharma 4.0 in clinical trials: A future-orientated perspective
|
Hariry, Reza Ebrahimi
|
|
|
27 |
1 |
p. 315-325
|
artikel
|
| 33 |
Vorinostat in autophagic cell death: A critical insight into autophagy-mediated, -associated and -dependent cell death for cancer prevention
|
Patra, Srimanta
|
|
|
27 |
1 |
p. 269-279
|
artikel
|
Tijdschrift beschrijving